Skip to content

IVI-guided Versus Angiography-guided PCI in Patients With Diabetes Mellitus

Intravascular Imaging-guided Versus Angiography-guided PCI in Patients With Diabetes Mellitus: the Muticenter, Randomized, Prospective IVI-DIABETES Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06380868
Acronym
IVI-DIABETES
Enrollment
1332
Registered
2024-04-24
Start date
2024-07-17
Completion date
2027-07-20
Last updated
2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

Intravascular ultrasound (IVUS) serves as a beneficial instrument during percutaneous coronary intervention (PCI) procedures, affording insight into lesion characteristics and stent implantation. The ULTIMATE trial recently evidenced that IVUS-guided Drug-Eluting Stent (DES) implantation notably ameliorated clinical outcomes in all-comers, especially in patients who underwent an optimal procedure defined by IVUS, as opposed to angiography guidance, resonating with findings from the IVUS-XPL study, OCTOBER trial, and RENOVATE COMPLEX PCI trial, further confirmed by more recent IVUS-ACS trial. Optical coherence tomography (OCT) has a resolution 10 times higher than that of IVUS and can provide valuable information at each step of PCI. Regrettably, a dearth of prospective, randomized, multicenter trials exists that scrutinize the benefits of IVI-guided as opposed to angiography-guided PCI in patients suffering from diabetes mellitus. However, several trials have presented subgroup analyses reporting the reduction of clinical events by IVUS but not OCT guidance in patients with diabetes mellitus, which served as the foundation for the design of this trial.

Detailed description

The current study hypothesizes that IVI-guided PCI will be superior with respect to target vessel failure (TVF), including cardiac death, target-vessel myocardial infarction (TVMI), or clinically-driven TVR when compared with angiography-guided PCI in patients with diabetes mellitus.

Interventions

PROCEDUREIntravascular imaging-guided PCI

Intravascular imaging including intravascular ultrasound or optical coherence tomography.

Deployment of a drug-eluting stent under angiography.

Sponsors

Nanjing First Hospital, Nanjing Medical University
Lead SponsorOTHER
Shanxi Provincial People's Hospital
CollaboratorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Randomization will be performed in the catheter laboratory by an invasive nurse. Staff in the catheter laboratory will be not blinded to the treatment allocation.

Intervention model description

Patients will undergo 1:1 randomization to either intravascular imaging (including intravascular ultrasound or optical coherence tomography)-guided DES implantation which will be the treatment group or Angio-guided DES implantation which will be the control group, stratified by research sites.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age between 18 \~ 80 years old, 2. Confirmed diabetes mellitus 3. Indications for undergoing percutaneous coronary intervention using a drug-eluting stent (Invasive or quantitative fractional flow reserve (QFR or FFR) \<0.80) 4. Silent angina, stable angina, unstable angina, or Non-ST-elevation myocardial infarction

Exclusion criteria

1. Cardiogenic shock 2. Previous coronary artery bypass graft (CABG) 3. Left ventricular ejection fraction \< 30% 4. Requiring oral anticoagulation medications 5. Any planned surgery within 12 months 6. Severe chronic kidney disease defined as an estimated glomerular filtration rate (eGFR) \< 20 ml/min/1.73m2 7. Platelet count \< 100,000 mm3 8. Contraindication to study medications or metal 9. Women of childbearing potential 10. Life expectancy \< 1 year 11. Any condition likely to interfere with study processes including medication compliance or follow-up visits (e.g. dementia, alcohol abuse, severe frailty, long distance to travel for follow-up visits, etc.)

Design outcomes

Primary

MeasureTime frameDescription
Rate of target vessel failure (TVF)At one-year since interventionsTVF is defined as a composite of cardiac death, target-vessel myocardial infraction, or clinically driven target vessel revascularization

Secondary

MeasureTime frameDescription
Rate of target vessel failure without procedure-related MIAt one-year since interventionsProcedural-related myocardial infarction (PMI) would be excluded from the calculation of TVF
Rate of cardiac deathAt one-year since interventionsAny death without clear reasons
Rate of all-cause deathAt one-year since interventionsAny death occurs within one-year follow-up
Rate of procedure-related myocardial infarction (PMI)Within 48 h since coronary intervention48 hours after coronary intervention
Rate of spontaneous myocardial infarction (SMI)Within one-year follow-upMI happens between 48 h and one-year since coronary intervention
Rate of clinically-driven revascularizationAt one-year since coronary artery interventionTarget vessel revascularization was defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel was defined as the entire major coronary vessel proximal and distal to the target lesion, which included upstream and downstream branches and the target lesion itself.
Rate of stent thrombosisAt one-year since coronary artery interventionDefinite or probable stent thrombosis

Countries

China

Contacts

CONTACTShao-Liang C Chen, MD
chmengx@126.com13605157029
CONTACTXiling Shou, MD
chmengx@hotmail.com+8618966700335
PRINCIPAL_INVESTIGATORJing Kan, MD

Nanjing First Hospital, Nanjing Medical University, and Shan'Xi Provincial People's Hospital, China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 20, 2026